<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431598</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00059192</org_study_id>
    <nct_id>NCT02431598</nct_id>
  </id_info>
  <brief_title>Eovist vs. Dotarem Healthy Volunteer MRI</brief_title>
  <official_title>Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes in volunteer breath-holding capacity in
      response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate
      dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These
      subjects will be given three, blinded, randomized injections while undergoing an MRI of their
      liver and holding their breath. During the scan, the subjects' oxygen saturation and heart
      rate will be closely monitored. Following the scan, the subjects will complete a
      questionnaire regarding the breath hold.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject-reported Dyspnea, as Measured by Questionnaire Responses</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
    <description>After each breath-hold, the MRI technologist asked the volunteer through the scanner microphone the following two questions, with responses based on a 5-point scale: A) How difficult was it to hold your breath? (1-Not at all; 5-Very difficult); B) Do you feel short of breath now? (1-Not at all; 5-Very short of breath). Responses were recorded for each breath-hold.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>O2 Saturation Following Contrast Administration</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Following Contrast Injection</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
    <description>Heart rate following contrast injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Transient Severe Motion (TSM) Based on Presence of Motion Artifacts at Arterial Phase Imaging</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
    <description>Arterial-phase breath-holding duration and motion artifacts after each agent were compared using the Mann-Whitney-U test and the McNemar test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Motion Artifacts at Arterial Phase Imaging, Measured on a 1-5 Scale</measure>
    <time_frame>following contrast administration, up to 5 minutes</time_frame>
    <description>no motion artifact
minimal motion artifact
moderate motion artifact
severe motion artifact
extensive motion artifact</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Transient Severe Arterial Phase Motion</condition>
  <arm_group>
    <arm_group_label>Eovist (gadoxetate disodium)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dotarem (gadoterate dimeglumine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoxetate disodium</intervention_name>
    <arm_group_label>Eovist (gadoxetate disodium)</arm_group_label>
    <other_name>Eovist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoterate dimeglumine</intervention_name>
    <arm_group_label>Dotarem (gadoterate dimeglumine)</arm_group_label>
    <other_name>Dotarem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - normal renal function (serum eGFR &gt;60)

        Exclusion Criteria:

          -  renal impairment

          -  allergy to gadolinium-based contrast

          -  metallic implanted devices

          -  claustrophobia

          -  pregnant and lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mustafa Bashir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <results_first_submitted>September 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eovist Crossover to Dotarem Crossover to Saline</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
        <group group_id="P2">
          <title>Dotarem Crossover to Eovist Crossover to Saline</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
        <group group_id="P3">
          <title>Eovist Crossover to Saline Crossover to Dotarem</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
        <group group_id="P4">
          <title>Saline Crossover to Dotarem Crossover to Eovist</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
        <group group_id="P5">
          <title>Dotarem Crossover to Saline Crossover to Eovist</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
        <group group_id="P6">
          <title>Saline Crossover to Eovist Crossover to Dotarem</title>
          <description>Subjects received the agents in this particular order during their MRI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eovistvs vs. Dotarem vs. Saline</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath</title>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <population>All participants received all three drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Eovist (Gadoxetate Disodium)</title>
          </group>
          <group group_id="O2">
            <title>Dotarem (Gadoterate Dimeglumine)</title>
          </group>
          <group group_id="O3">
            <title>Saline</title>
          </group>
        </group_list>
        <measure>
          <title>Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath</title>
          <population>All participants received all three drugs.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="8" upper_limit="117"/>
                    <measurement group_id="O2" value="38" lower_limit="23" upper_limit="125"/>
                    <measurement group_id="O3" value="35" lower_limit="20" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject-reported Dyspnea, as Measured by Questionnaire Responses</title>
        <description>After each breath-hold, the MRI technologist asked the volunteer through the scanner microphone the following two questions, with responses based on a 5-point scale: A) How difficult was it to hold your breath? (1-Not at all; 5-Very difficult); B) Do you feel short of breath now? (1-Not at all; 5-Very short of breath). Responses were recorded for each breath-hold.</description>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eovist (Gadoxetate Disodium)</title>
            <description>Injection of gadoxetate disodium</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Injection of normal saline</description>
          </group>
          <group group_id="O3">
            <title>Dotarem (Gadoterate Dimeglumine)</title>
            <description>Injection of gadoterate dimeglumine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject-reported Dyspnea, as Measured by Questionnaire Responses</title>
          <description>After each breath-hold, the MRI technologist asked the volunteer through the scanner microphone the following two questions, with responses based on a 5-point scale: A) How difficult was it to hold your breath? (1-Not at all; 5-Very difficult); B) Do you feel short of breath now? (1-Not at all; 5-Very short of breath). Responses were recorded for each breath-hold.</description>
          <units>units on a scale (1-5)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Question A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.1"/>
                    <measurement group_id="O2" value="1.8" spread="1.1"/>
                    <measurement group_id="O3" value="1.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Question B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                    <measurement group_id="O2" value="1.1" spread="0.5"/>
                    <measurement group_id="O3" value="1.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>O2 Saturation Following Contrast Administration</title>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eovist (Gadoxetate Disodium)</title>
            <description>Injection of gadoxetate disodium</description>
          </group>
          <group group_id="O2">
            <title>Dotarem (Gadoterate Dimeglumine)</title>
            <description>Injection of gadoterate dimeglumine</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Injection of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>O2 Saturation Following Contrast Administration</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="2"/>
                    <measurement group_id="O2" value="98" spread="2"/>
                    <measurement group_id="O3" value="98" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Following Contrast Injection</title>
        <description>Heart rate following contrast injection</description>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eovist (Gadoxetate Disodium)</title>
            <description>Injection of gadoxetate disodium</description>
          </group>
          <group group_id="O2">
            <title>Dotarem (Gadoterate Dimeglumine)</title>
            <description>Injection of gadoterate dimeglumine</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Injection of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Following Contrast Injection</title>
          <description>Heart rate following contrast injection</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="12"/>
                    <measurement group_id="O2" value="70" spread="12"/>
                    <measurement group_id="O3" value="70" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Transient Severe Motion (TSM) Based on Presence of Motion Artifacts at Arterial Phase Imaging</title>
        <description>Arterial-phase breath-holding duration and motion artifacts after each agent were compared using the Mann-Whitney-U test and the McNemar test.</description>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eovist (Gadoxetate Disodium)</title>
            <description>Injection of gadoxetate disodium</description>
          </group>
          <group group_id="O2">
            <title>Dotarem (Gadoterate Dimeglumine)</title>
            <description>Injection of gadoterate dimeglumine</description>
          </group>
          <group group_id="O3">
            <title>Saline</title>
            <description>Injection of normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Transient Severe Motion (TSM) Based on Presence of Motion Artifacts at Arterial Phase Imaging</title>
          <description>Arterial-phase breath-holding duration and motion artifacts after each agent were compared using the Mann-Whitney-U test and the McNemar test.</description>
          <units>percentage of participants with TSM</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Motion Artifacts at Arterial Phase Imaging, Measured on a 1-5 Scale</title>
        <description>no motion artifact
minimal motion artifact
moderate motion artifact
severe motion artifact
extensive motion artifact</description>
        <time_frame>following contrast administration, up to 5 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Contrast Phase</title>
            <description>Prior to contrast injection</description>
          </group>
          <group group_id="O2">
            <title>Arterial Phase</title>
            <description>Imaging obtained during arterial phase</description>
          </group>
          <group group_id="O3">
            <title>Portal Venous Phase</title>
            <description>Imaging obtained during portal venous phase</description>
          </group>
          <group group_id="O4">
            <title>Last Dynamic Phase</title>
            <description>Imaging obtained during late dynamic phase</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Motion Artifacts at Arterial Phase Imaging, Measured on a 1-5 Scale</title>
          <description>no motion artifact
minimal motion artifact
moderate motion artifact
severe motion artifact
extensive motion artifact</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eovist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="2.4" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Saline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="2.2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="2.1" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dotarem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eovist (Gadoxetate Disodium)</title>
        </group>
        <group group_id="E2">
          <title>Dotarem (Gadoterate Dimeglumine)</title>
        </group>
        <group group_id="E3">
          <title>Saline</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mustafa Bashir</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-8111</phone>
      <email>mustafa.bashir@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

